A Randomized, Double-Blind Phase 2 Clinical Trial of Blosozumab, a Sclerostin Antibody, in Postmenopausal Women with Low Bone Mineral Density
Robert R. Recker(Creighton University), Stephen L. Myers(Eli Lilly (United States)), Michael A. Bolognese, Jahangir Alam(Eli Lilly (United States)), Hideaki Sowa, John H. Krege(Eli Lilly (United States)), Bruce Mitlak(Radius Health (United States)), Deborah A. Robins(Eli Lilly (United States)), Leijun Hu(Eli Lilly (United States)), Toshio Matsumoto(Tokushima University), Alan Y. Chiang(Eli Lilly (United States)), Charles Benson(Eli Lilly (United States))
Cited by 291
Related Papers
Generation and reproductive phenotypes of mice lacking estrogen receptor β
|Proceedings of the National Academy of Sciences|1998|1.7k
Effects of Raloxifene on Bone Mineral Density, Serum Cholesterol Concentrations, and Uterine Endometrium in Postmenopausal Women
|New England Journal of Medicine|1997|1.6k
Effects of Oral Ibandronate Administered Daily or Intermittently on Fracture Risk in Postmenopausal Osteoporosis
|Journal of Bone and Mineral Research|2004|1.2k
Elevated blood pressures in mice lacking endothelial nitric oxide synthase
|Proceedings of the National Academy of Sciences|1996|903
A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia
|New England Journal of Medicine|2014|712